We utilized a second generation anti-CD19 4-1BBζ CAR (aCD19 CAR) for these studies because it has displayed potent anti-tumor activity in clinical studies20 and we hypothesized that it would present a stringent challenge for PD-L1 mediated suppression of CAR T cell function. Here, CD274 is linked to neoplasm.